WEBULL
News
GNMSF
308.00
NaN%
--
Harbor Small Cap Growth Fund Q4 2025 Portfolio Performance
Seeking Alpha · 01/30 03:30
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Barchart · 01/29 11:49
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2025
Barchart · 01/21 05:23
Genmab to Hold 2025 R&D Update and ASH Data Review Meeting
Barchart · 12/11/2025 01:00
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
Barchart · 12/07/2025 06:50
Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes
Barchart · 12/03/2025 14:03
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
Barchart · 12/01/2025 15:24
Thanksgiving: Top 10 Most Innovative BioPharma Drugs In Phase 3
Seeking Alpha · 11/27/2025 12:20
Grant of Restricted Stock Units and Warrants to Employees in Genmab
Barchart · 11/20/2025 14:02
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Barchart · 11/19/2025 11:56
Genmab Announces Pricing of Private Offering of Senior Secured Notes and Senior Unsecured Notes and Completion of Syndication of New Senior Secured Term Loan Facility
Barchart · 11/18/2025 15:01
Capital Increase in Genmab as a Result of Employee Warrant Exercise
Barchart · 11/18/2025 13:58
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
Barchart · 11/18/2025 10:30
Genmab Provides Certain Information Disclosed in Connection with Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes
Barchart · 11/10/2025 09:51
Genmab Announces Proposed Private Offering of Senior Secured Notes and Senior Unsecured Notes and Syndication of New Senior Secured Term Loan Facility
Barchart · 11/10/2025 06:12
Genmab Announces Financial Results for the Nine Months of 2025
Barchart · 11/06/2025 10:02
Genmab to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference in London
Barchart · 11/05/2025 11:58
Genmab Commences Tender Offer for All Issued and Outstanding Common Shares of Merus N.V.
Barchart · 10/21/2025 07:12
Moderna Vs BioNTech: Who's Winning The Post-COVID Race
Seeking Alpha · 10/18/2025 13:30
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S®) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
Barchart · 10/18/2025 05:00
More
Webull provides a variety of real-time GNMSF stock news. You can receive the latest news about Genmab A/S through multiple platforms. This information may help you make smarter investment decisions.
About GNMSF
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.